soul trial oral semaglutide cardiovascular outcomes results 2025 (NEJM 2025): led to a 14% ↓ in major CV events vs placebo in T2DM with ASCVD or CKD — no ↑ in serious AEs. #Semaglutide #CardioDiabetes #updatesinmedicine Projected reduction in major adverse
Pay in 4 interest-free payments of $5.48 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14























![[With Card Slot] OPPO Reno13 F 4G/5G Premium Leather Shockproof Wallet Series Case OPPO Pad 3 Pro](https://cdn.shopify.com/s/files/1/0085/9150/7533/files/014_5196293f-9867-4d80-aa50-95e0ec29bba0.png?v=1744785302)

